Another explanation comes from the studies of Tanner et al. [29] who have shown that mutations affecting exons 1–4 of human AMN (OMIM 261100, megaloblastic anemia, MGA1) do not prevent the production variant transcripts and polypeptides resulting from alternative transcriptional start sites and alternative translation initiation sites. The gene discussed is CUBN; the disease is megaloblastic anemia.